PGEN · Why this verdict
Why Precigen (PGEN) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score4.3/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Precigen is a cash-burning biotech with a dangerously weak quality profile, but extreme momentum signals and analyst upside of 159% suggest a speculative setup with limited near-term downside if short-interest pressure resolves.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Free cash flow is negative at -285% of revenue and the Piotroski F-Score is only 3 out of 9, placing quality well below the minimum investment threshold at a score of 2.2 out of 10. Quality breakdown | FCF loss rate narrows meaningfully and quality score rises above 4.0 within 12 months. | →Stable |
| CounterCash-burning biotechs often dilute shareholders before reaching profitability, and a 3/9 Piotroski score signals broad financial deterioration that may persist. | ||
Short interest stands at 21% with an elevated put-to-call ratio of 2.33, indicating significant bearish positioning that could suppress price recovery or trigger forced selling. Key risks | Short interest falls below 15% as bearish positioning unwinds over the next 12 months. | →Stable |
| CounterHigh short interest can compress further or result in a short squeeze, and the elevated put-to-call ratio may reflect informed hedging rather than speculative shorting. | ||
The stock exhibits a golden cross pattern above all moving averages with RSI at 60 and MACD bullish, while the OBV shows rising volume accumulation — momentum score is 7.5 out of 10. Momentum breakdown | Price sustains above all major moving averages and momentum score remains above 6.0 for at least 2 consecutive quarters. | →Stable |
| CounterTechnical breakouts in low-quality small-cap biotechs frequently fail; the stock is near a 52-week position of 7.6 and could reverse if sentiment turns. | ||
With only 2 analysts covering the stock, consensus price target implies 159% upside from current levels, and the asymmetry ratio is 8.0 against a 15% downside stop. Sentiment breakdown | Stock price rises above $7.00 within 12 months as analyst coverage expands or the thesis is validated. | →Stable |
| CounterA two-analyst consensus with light coverage is an unreliable signal; targets can be stale or reflect hope rather than grounded forecasts. | ||
Free cash flow is negative at -285% of revenue and the Piotroski F-Score is only 3 out of 9, placing quality well below the minimum investment threshold at a score of 2.2 out of 10.
→StableQuality breakdown
- Expectation
- FCF loss rate narrows meaningfully and quality score rises above 4.0 within 12 months.
CounterCash-burning biotechs often dilute shareholders before reaching profitability, and a 3/9 Piotroski score signals broad financial deterioration that may persist.
Short interest stands at 21% with an elevated put-to-call ratio of 2.33, indicating significant bearish positioning that could suppress price recovery or trigger forced selling.
→StableKey risks
- Expectation
- Short interest falls below 15% as bearish positioning unwinds over the next 12 months.
CounterHigh short interest can compress further or result in a short squeeze, and the elevated put-to-call ratio may reflect informed hedging rather than speculative shorting.
The stock exhibits a golden cross pattern above all moving averages with RSI at 60 and MACD bullish, while the OBV shows rising volume accumulation — momentum score is 7.5 out of 10.
→StableMomentum breakdown
- Expectation
- Price sustains above all major moving averages and momentum score remains above 6.0 for at least 2 consecutive quarters.
CounterTechnical breakouts in low-quality small-cap biotechs frequently fail; the stock is near a 52-week position of 7.6 and could reverse if sentiment turns.
With only 2 analysts covering the stock, consensus price target implies 159% upside from current levels, and the asymmetry ratio is 8.0 against a 15% downside stop.
→StableSentiment breakdown
- Expectation
- Stock price rises above $7.00 within 12 months as analyst coverage expands or the thesis is validated.
CounterA two-analyst consensus with light coverage is an unreliable signal; targets can be stale or reflect hope rather than grounded forecasts.
Per-dimension breakdown
Quality
2.2/10data confidence 100%| Component | Sub-score |
|---|---|
| ROA | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 8.2 |
| FCF quality | 0.0 |
| Moat | 4.2 |
| Piotroski F | 3.3 |
- ▸Cash-burning: FCF -285% of revenue
- ▸No competitive moat
- ▸Weak Piotroski F-Score: 3/9
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
6.5/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.9 |
| MACD | 9.5 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 0.0 |
- ▸Overbought (RSI 83)
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
7.0/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 5.9 |
| Price target | 10.0 |
| erm sentiment | 5.0 |
- ▸Light analyst coverage (2.0) — signal dampened
- ▸Analyst upside: 123%
Insider
3.0/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 2.0 |
| insider conviction | 2.0 |
| holder change | 5.1 |
- ▸Heavy insider selling — $16,897,904 (0.878% of mkt cap)
Peer rank
2.6/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 0.5 |
| quality rank | 0.0 |
| growth rank | 10.0 |
- ▸Industry growth leader
Technical
3.7/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.6 |
| support resistance | 0.4 |
| 52w position | 9.7 |
| gap | 4.0 |
Risk (lower is worse)
2.7/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 1.4 |
| days to cover | 0.0 |
| volatility | 0.0 |
| put call | 10.0 |
| implied vol | 0.0 |
| max pain risk | 3.0 |
| beta | 6.8 |
| debt equity | 0.1 |
- ▸High short interest justified: 21%
- ▸High IV: 91%
- ▸Above max pain $2
Catalyst
3.9/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 5.6 |
| earnings timing | 5.0 |
| surprise avg | 0.0 |
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (8)
- MOMENTUM:6.5>=5.5
- ASYMMETRY:6.0>=1.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:47d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)
none
Warning (0)
none
Reward-to-Risk
5.97
Upside
+89.5%
Downside
15.0%
Sizing output
AVOID
SetupUNKNOWN — No clear chart pattern; technical signals are mixed
EdgeNO_EDGE — No clear edge identified
SuitabilityAGGRESSIVE — MCap $1.9B<$5B
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Sentiment at 7.0 could not lift the engine output above the verdict floor.
The strongest dimensions are Sentiment at 7.0, Momentum at 6.5, and Value at 5.0; the weakest are Quality at 2.2, Peer rank at 2.6, and Risk (lower is worse) at 2.7. The V9 engine cleared all gates, producing an asymmetric reward-to-risk of 5.97 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Free cash flow is negative at -285% of revenue and the Piotroski F-Score is only 3 out of 9, placing quality well below the minimum investment threshold at a score of 2.2 out of 10.
Trip ifFCF loss rate exceeds 300% of revenue for 2 consecutive quarters, indicating quality deterioration beyond current levels.
- P2Short interest stands at 21% with an elevated put-to-call ratio of 2.33, indicating significant bearish positioning that could suppress price recovery or trigger forced selling.
Trip ifShort interest rises above 25% or put-to-call ratio exceeds 3.0, signaling accelerating bearish positioning.
- P3The stock exhibits a golden cross pattern above all moving averages with RSI at 60 and MACD bullish, while the OBV shows rising volume accumulation — momentum score is 7.5 out of 10.
Trip ifPrice drops below the 200-day moving average and RSI falls below 40 for 2 consecutive weeks.
- P4With only 2 analysts covering the stock, consensus price target implies 159% upside from current levels, and the asymmetry ratio is 8.0 against a 15% downside stop.
Trip ifAnalyst consensus price target falls below $6.00, reducing implied upside to less than 25% from current price.